BioSpace News Archive

BostonGene Corporation, a biomedical software company, today announced the appointment of Nathan Fowler, M.D., to the newly created position of Chief Medical Officer (CMO).

Debiopharm announced that the American Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for Debio 1143, the most clinically advanced IAP antagonist, for the treatment of patients with confirmed diagnosis

Vycor Medical, Inc. (OTCQB: VYCO) Jose Romano, Chief of the Stroke Division at the University of Miami Miller School of Medicine, co-authored a recently published international study that shows that visual rehabilitation is effective for patients who have suffered vision loss related to stroke or traumatic brain injury.

PolyPid Ltd. , a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that the first patient has been enrolled and randomized in a Phase 3 clinical trial called SHIELD

The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, one of the largest hyperbaric medicine centers in the world, announced study results indicating its hyperbaric oxygen therapy (HBOT) protocols induce significant improvement in most cognitive domains of patients who suffered stroke – even months to years after the event.

- Datavant has hired Aden Fine as General Counsel and Chief Privacy Officer - Datavant has hired Dongting Yu, PhD, as Head of Security Engineering - David Shulkin (former Secretary of Veterans Affairs) and Andrew von Eschenbach (former FDA Commissioner and NCI Director) appointed to Datavant Advisory Board

DataLink Software (DataLink), a leading solution to enhance interoperability, reduce costs, improve quality scores and ensure risk adjustment accuracy, has achieved the National Committee for Quality Assurance (NCQA) certification for the Healthcare Effectiveness Data and Information Set (HEDIS®) Health Plan 2020 for all measures.

Company achieves milestone, completes more than 300 COLORFUL COMMUNITIES projects since 2015

As I have previously communicated, the FDA has been closely monitoring the supply chain with the expectation that the COVID-19 outbreak would likely impact the medical product supply chain, including potential disruptions to supply or shortages of critical medical products in the U.S.

Two executives from the National Alliance of Healthcare Purchasers Coalitions lend perspective on the role of employers in promoting high-value preventive care.